Previous 10 | Next 10 |
− Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation − − Companies Expect to Start Human Clinical Trials at or Around Year-End 2020 – Vir Biotechnology, Inc. (Nasdaq: VIR) ...
Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2020 on Wednesday, May 6, 2020, before the U.S. financial markets open. Management will provide an update on ...
BeiGene Reports Phase 3 Trial Meeting Primary Endpoint BeiGene Ltd. (BGNE) reported that its Phase 3 trial assessing tislelizumab in combination with pemetrexed and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival ((PFS)) compared to...
Vir Biotechnology (NASDAQ: VIR) shares have soared 134% since the start of the year as the company jumped into the race to find a treatment for COVID-19, the illness caused by the novel coronavirus. Vir's gains -- and gains for other drugmakers working on COVID-19 treatment and prevention --...
SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase 1 trial in healthy volunteers of VIR-2218, an investigational small interfering ribonucleic a...
Doubt has seized investors around the world. Economists are still determining the likely effects of the coronavirus pandemic on growth, employment, and industries ranging from auto insurance to animal health. That all suggests now is not a great time to invest in riskier assets, but investors ...
Alnylam Pharmaceuticals Receives $2 Billion Funding from Blackstone Alnylam Pharmaceuticals ( ALNY ) announced that Blackstone Group (BX) has decided to invest up to $2 billion through a combination of debt and equity. The funding will impart the much-needed liquidity to the company and wi...
The FDA grants Fast Track status for Alnylam Pharmaceuticals' (NASDAQ: ALNY ) RNAi therapeutic vutrisiran for the treatment of adults with polyneuropathy (damage to multiple peripheral nerves) of hereditary transthyretin-mediated (hATTR) amyloidosis , a rare inherited disorder ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to vutrisiran, an investigational therapeutic for the treatment of the polyneuropathy of hereditary transt...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...